Grifols to double Revolving Credit Facility to $2 billion following strong support from global bank syndicate

Barcelona, Spain, March 16, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, has received commitments from banks for a new Revolving Credit Facility (RCF) of approximately $2 billion supported by a syndicate of leading international banks. This new facility would more than double the size of the previous $938 million RCF and have a maturity of 6.5 years, further strengthening Grifols’ financial flexibility and balance sheet. The new facility is subject to completion of the refinancing of the company’s existing Term Loan B (TLB) by 31 May 2026, consistent with the company’s announced plans.

Pursuant to the commitments, the margin applicable to the new facility would be reduced from 300 basis points to 200 basis points, with the potential to decline further to 125 bps subject to the company progressing on its deleveraging targets.

Demand from lenders to participate in the new facility significantly exceeded the final allocation of commitments, underscoring strong support for Grifols’ deleveraging and free cashflow improvement progress from a group of global banks after completion of their due diligence and final approvals. The Joint Arrangers selected include Bank of America, JPMorgan, Santander, DNB, Citibank, Commerzbank, Deutsche Bank, Goldman Sachs Bank Europe SE, HSBC, Helaba, UBS, ING and Nomura.

Rahul Srinivasan, Chief Financial Officer of Grifols, said: “The significant upsize and attractive terms of the new RCF facility is further validation of Grifols’ highly differentiated strategy and unique positioning, that has been many years in the making, and will support our continued Revenue growth, EBITDA growth and margin improvement, enhanced free cash flow generation and deleveraging path.”

Strong re-rating momentum recognised by credit rating agencies

Recent positive rating actions by major credit agencies have recognised Grifols’ improving operating performance, stronger cash flow generation and significant progress on deleveraging.

Notably, S&P Global Ratings has upgraded the company’s issuer credit rating by two notches in the last 18 months to BB- with a stable outlook. Similarly, Moody’s and Fitch Ratings have also improved Grifols rating and / or outlook, highlighting the company’s strengthening financial profile, improving leverage trajectory and continued progress in restoring balance sheet strength.^*

^* A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.